Shopping Cart
- Remove All
Your shopping cart is currently empty
Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $38 | In Stock | |
| 10 mg | $61 | In Stock | |
| 25 mg | $121 | In Stock | |
| 50 mg | $188 | In Stock | |
| 100 mg | $312 | In Stock | |
| 200 mg | $538 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $42 | In Stock |
| Description | Tapinarof (Benvitimod) is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease. |
| Targets&IC50 | AhR:13 nM(EC50) |
| In vitro | Tapinarof activates the AhR pathway through direct binding, inducing dose-dependent nuclear translocation of AhR in immortalized keratinocytes (HaCaT). |
| In vivo | Tapinarof mediates its anti-inflammatory effects via the AhR pathway in IMQ-treated mice. In mice expressing AhR on a C57Bl/6 background, both Tapinarof and 6-formylindolo(3,2-b)carbazole (FICZ) significantly lower clinical inflammation scores. Conversely, AhR knockout (KO) mice exhibit no such anti-inflammatory response to Tapinarof. FICZ serves as a benchmark in these experiments, demonstrating comparable reduction in inflammation in wild-type mice, but ineffective in AhR KO mice. |
| Synonyms | WBI 1001, GSK2894512, Benvitimod |
| Molecular Weight | 254.32 |
| Formula | C17H18O2 |
| Cas No. | 79338-84-4 |
| Smiles | CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O |
| Relative Density. | 1.158 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (216.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.